BMRN – BioMarin Pharmaceutical Inc.

BMRN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.48

Margin Of Safety %

Put/Call OI Ratio

0.59

EPS Next Q Diff

0.95

EPS Last/This Y

3.52

EPS This/Next Y

1.39

Price

54.12

Target Price

88.82

Analyst Recom

1.58

Performance Q

-10.01

Upside

15.1%

Beta

0.3

Ticker: BMRN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	BMRN	61.72	0.66	0.04	36552
2026-03-02	BMRN	59.73	0.53	0.90	42112
2026-03-03	BMRN	58.52	0.49	0.03	41639
2026-03-04	BMRN	60.43	0.47	0.05	42687
2026-03-05	BMRN	60.52	0.48	0.01	42645
2026-03-06	BMRN	61.14	0.48	0.09	42517
2026-03-09	BMRN	60.86	0.48	0.52	42601
2026-03-10	BMRN	60.89	0.48	0.22	42484
2026-03-11	BMRN	60.32	0.46	0.10	43004
2026-03-12	BMRN	59.08	0.46	0.23	43061
2026-03-13	BMRN	59.07	0.46	0.29	43061
2026-03-17	BMRN	56.02	0.47	0.44	42776
2026-03-18	BMRN	55.55	0.48	1.11	42799
2026-03-19	BMRN	55.03	0.51	5.97	44912
2026-03-20	BMRN	54.15	0.47	0.62	43845
2026-03-23	BMRN	54.78	0.58	0.03	32134
2026-03-24	BMRN	54.08	0.58	0.23	32139
2026-03-25	BMRN	55.61	0.58	0.44	32175
2026-03-26	BMRN	55.55	0.58	0.26	32522
2026-03-27	BMRN	54.13	0.59	0.09	32836
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	BMRN	61.71	-9.4	503.8	5.21
2026-03-02	BMRN	59.73	-7.3	18.8	5.34
2026-03-03	BMRN	58.53	-7.7	28.2	5.34
2026-03-04	BMRN	60.44	-7.7	266.6	5.34
2026-03-05	BMRN	60.57	-11.1	242.5	5.34
2026-03-06	BMRN	61.12	-11.1	247.9	5.34
2026-03-09	BMRN	60.87	-11.1	237.3	5.34
2026-03-10	BMRN	60.91	-11.1	241.0	5.34
2026-03-11	BMRN	60.30	-11.1	232.8	5.34
2026-03-12	BMRN	59.08	-11.4	224.1	5.34
2026-03-13	BMRN	58.50	-11.4	140.9	5.34
2026-03-17	BMRN	56.04	-12.3	130.7	5.34
2026-03-18	BMRN	55.43	-12.3	139.8	5.34
2026-03-19	BMRN	55.02	-12.3	142.4	5.34
2026-03-20	BMRN	54.13	-11.3	136.6	5.34
2026-03-23	BMRN	54.79	-11.3	156.0	5.34
2026-03-24	BMRN	54.12	-11.6	139.1	5.34
2026-03-25	BMRN	55.61	-11.6	167.5	5.34
2026-03-26	BMRN	55.54	-11.6	147.0	5.34
2026-03-27	BMRN	54.12	-11.6	129.6	5.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	BMRN	-1.16	-0.46	4.55
2026-03-02	BMRN	-1.16	3.92	4.55
2026-03-03	BMRN	-1.16	3.92	4.55
2026-03-04	BMRN	-1.16	3.92	4.55
2026-03-05	BMRN	-1.16	3.92	4.55
2026-03-06	BMRN	-1.16	3.92	4.55
2026-03-09	BMRN	-1.16	3.91	4.55
2026-03-10	BMRN	-1.16	3.91	4.55
2026-03-11	BMRN	-1.16	3.91	4.36
2026-03-12	BMRN	-1.16	3.91	4.36
2026-03-13	BMRN	-1.73	3.91	4.36
2026-03-17	BMRN	-1.73	3.97	4.36
2026-03-18	BMRN	-1.73	3.97	4.36
2026-03-19	BMRN	-1.73	3.97	4.36
2026-03-20	BMRN	-1.73	3.97	4.36
2026-03-23	BMRN	-1.73	4.01	4.36
2026-03-24	BMRN	-1.73	4.01	4.36
2026-03-25	BMRN	-1.73	4.01	4.48
2026-03-26	BMRN	-1.73	4.01	4.48
2026-03-27	BMRN	-1.73	4.01	4.48
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.15

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

1.1

Insider Transactions

-1.73

Institutional Transactions

4.01

Beta

0.3

Average Sales Estimate Current Quarter

754

Average Sales Estimate Next Quarter

952

Fair Value

73.48

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-56.1

Target Price

88.82

P/E

30.39

Forward P/E

10.09

PEG

0.18

P/S

3.21

P/B

1.71

P/Free Cash Flow

14.36

EPS

1.78

Average EPS Est. Cur. Y

5.34

EPS Next Y. (Est.)

6.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.76

Relative Volume

0.62

Return on Equity vs Sector %

-21.6

Return on Equity vs Industry %

-5.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

129.6

◆ BMRN Healthcare

$54.14

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

9/15

Valuation

20/20

TP/AR

1/10

Options

5/10

RSI

34.7

Range 1M

11.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

21/30

Estimates

6/20

Inst/Vol

4/15

Options

9/10

EPS Yr

140.1%

EPS NY

24.1%

52W%

16.4%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +191.1% upside

Quality

14/30

Valuation

28/30

Growth

18/25

Stability

9/10

LT Trend

4/5

Upside

+191.1%

Quality

MoS

36%

BioMarin Pharmaceutical Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 3221

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

BMRN

Latest News

—

Caricamento notizie per BMRN…

stock quote shares BMRN – BioMarin Pharmaceutical Inc. Stock Price stock today

news today BMRN – BioMarin Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BMRN – BioMarin Pharmaceutical Inc. yahoo finance google finance

stock history BMRN – BioMarin Pharmaceutical Inc. invest stock market

stock prices BMRN premarket after hours

ticker BMRN fair value insiders trading

BMRN – BioMarin Pharmaceutical Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: BMRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y